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Polymers like cellulose (MethocelTM K100MPRCR, K15MPRCR
and E4MCR) at different proportions (15-35%) were used to slow
the release of theophylline (100 mg) from capsules. Volumetric
method for powder filling capsules was used to prepare the
capsules. Drug release from capsules was performed using
apparatus 1, at 100 rpm and 900 mL of intestinal medium without
enzymes (pH 7.5), at 37 °C, following the USP 28th ed. (Test 8).
Dissolution profiles were compared to two batches of commercial
extended-release capsules. Capsules compounded with 35% (wt/
wt) of MethocelTM E4MCR showed dissolution profile according
to the official especifications. Similar results were reproduced with
other ten compounded batches. Commercial extended-release
capsules containing theophylline pellets (100 mg) showed quick
drug release when submitted to the same test, indicating that, in
these conditions, the capsules did not show prolonged release.
Mathematical models like zero-order, first-order and Higuchi were
applied in kinetic studies of theophylline release from the
compounded capsules. Polymers were efficient to control the
release of theophylline in capsules involving diffusion and erosion
as mechanisms, and that first-order model was the best fitted one
for theophylline matrix capsules. These results support that
compounded extended-release capsules can be prepared, since the
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Compounded capsules have some advantages, like
adjusting the dosage to the therapeutic patient needs,
considering weight, therapeutic objective and side effects.
When patients require specific individualized therapy,
pharmacists are called upon by physicians to compound a
wide range of different products, including extended-
release and slow-release capsules (Bogner, Szwejkowski,
Houston, 2001).
The modified release term has been used to describe
many kinds of therapeutic and/or pharmacokinetic
objectives, including sustained-release, sustained action,
prolonged action, slow-release, delayed-release, etc
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(Shargel, Yu, 1999). Extended-release dosage forms have
been extensively carried out several decades ago.
Production of tablets and capsules with microgranules has
been described applying various materials as cellulose and
methacrylic acid derivatives (McGinity, Fukuda, Peppas,
2006; Zheng, Sauer, McGinity, 2005; Lopes, Costa, Lobo,
2005; Fu et al., 2004; McGinity et al., 2004; Young,
Koleng, McGinity, 2002; Siepmann et al., 2000; Ishikawa
et al., 2000)
Compounded, slow-release and extended-release
capsules has been part of a group called matrix systems and
the most common technique to obtain these matrices
involves basically the simple mixture of the drug with an
inert, hydrophobic or hydrophilic matrix that can be
encapsulated (Ojantakanen et al., 1993).
There are few published researches with compounded
matrix capsules. Webster, Al-AlChi, Greenwood (1999)
studied dissolution profiles of slow-release capsules with
morphine sulfate. These authors claimed that these capsules
can be an adequate alternative for the administration of
morphine sulfate, based on its release, similar to that of the
commercial medications.
In another study with morphine sulfate, the authors
got six slow-release capsules formulations with 300 mg
dose, prolonging the release with HPMC K100M polymer
(Bogner, Szwejkowski, Houston, 2001).
Hydrophilic matrix capsules were also studied with
micronized hormones, like progesterone, HPMC E4M
Premium and excipients. They were mixed and compacted
in gelatin hard capsules. It was concluded that the use of
slow-release matrices prolonged the hormone absorption
for many hours, allowing the patient to decrease the dose
frequency. However, the authors reported the necessity of
further pharmacokinetic studies, without which no
affirmation could be made about the bioidentical hormones
release profiles from slow-release capsules (Timmons,
Timmons, 2002).
Theophylline is a good candidate to be encapsulated
in slow-release capsules, since the treatment of obstructive
chronic pulmonary disease and night crisis depend on
keeping seric levels of the drug constant. This explains the
existence of a large number of studies about modified
release dosage forms with theophylline (Vendruscolo et al.,
2005; Zheng, Sauer, McGinity, 2005; McGinity et al.,
2005; Ojoe et al., 2005; Chambin et al., 2004; Young,
Koleng, McGinity, 2002; Pather et al., 1998).
In spite of these works, there are no studies that prove
the compounded extended-release capsules can reduce the
drug release in accordance to the official requirements and
also present inter-batch uniformity on the drug release
profiles.
This research had the purpose of obtaining slow-
release compounded capsules with theophylline 100 mg
dose, using cellulose derivatives in different rates,
studying the “in vitro” drug release. Results were
compared to the theophylline release from brand
medication (capsules with microgranules).
Reproducibility of theophylline release from different
batches of capsules was also studied.
MATERIAL AND METHODS
The following materials of pharmaceutical grade
were used to compound matrix capsules: anhydrous
theophylline 99.80% (supplied by Ariston),
hydroxypropylmethylcellulose – MethocelTM
K100MPRCR, E4MCR and K15MPRCR (Dow
ChemicalTM), lactose M200 (GalenaTM). Gastric fluid (pH
1.2) and intestinal fluid (pH 7.5) were prepared, according
to United States Pharmacopeia, 28th ed. (2005), with
Merck analytic grade reagents. Anhydrous theophylline
99.80% was used for analytical determinations. Colourless,
number size 1 capsules (Cardinal HealthTM).
Commercial capsules with prolonged-release
microgranules (same manufacturer).
Laboratory B1 (Brand Medication): capsules with
100 mg of prolonged-release theophylline microgranules,
batch Z95429; fabrication: 06/2003; beyond-use date: 06/
2006;
Laboratory B2 (Brand Medication): capsules with
100 mg of prolonged-release theophylline microgranules,
batch Z100857; fabrication: 01/2004; beyond-use date: 12/
2006;
Formulations
Six different slow-release formulations of capsules
with 100 mg of theophylline were prepared, using
volumetric method for powder filling capsules in a manu-
al encapsulator (MultilaborTM) (Allen, 1999). The
composition of the compounded capsules is presented on
the Table I.
All the components were sieved in 0.090 mm sieve
(170 mesh). The drug and the polymer were then weighted.
Their apparent volumes were measured in a graduated
cylinder (50 mL) and the powders were settled down. The
graduated cylinder was gently tapped 10 times and was
filled with lactose as excipient. The powders were mixtured
in a plastic bag for 10 minutes. All the powder was
homogenized another 10 minutes in a mortar.
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The powders were carefully spread on the manual
encapsulator until the content was completely inside the
capsules, and were settled down by tapping the manual
encapsulator 10 times. The caps were put over the capsules
bodies and locked. Fifty capsules of each batch were
prepared.
Weight variation
Twenty capsules of each formulation were
individually weighted and average, standard deviation and
variation coefficient were calculated. The results were
compared to the specifications of USP 28th ed. (2005).
Assay
An in-house spectrophotometric validated method, in
pH 7.5 phosphate buffer solution, at 271 nm, was used to
quantify the theophylline in the capsules. Samples of
powders, corresponding to 100 mg of theophylline were
taken and transferred to a volumetric flask (100.0 mL).
About 50 mL of ethylic alcohol were added and the
volumetric flask was sonicated for 40 minutes. The volu-
me was completed with ethylic alcohol. The solution was
centrifugated for 20 minutes and aliquots of 1 mL were
taken and diluted into a 100.0 mL volumetric flask with 7.5
pH simulated intestinal fluid.
Sample solutions were recorded in a Beckman
Coulter, DU 640, spectrophotometer at 271 nm, in
comparison with 10 µg/mL theophylline standard solution,
in the same medium. The tests were performed in duplicate.
Drug release
The following test was performed according to
American Pharmacopeia 28th ed., for Theophylline
Extended-Release Capsules Test 8, using apparatus 1
(basket) with 100 rpm stirring and temperature of 37 °C ±
0.5 °C. A 7.5 pH simulated intestinal fluid (without
enzyme) was used as medium (United States
Pharmacopeia, 2005).
Aliquots of 10 mL were withdrawn in different times
(15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 420 and 480
minutes) from the beginning of the test and the medium was
replaced with equal volume at the same temperature. The
aliquots were then centrifuged, diluted and quantified by
ultraviolet spectrophotometric analysis, using a Standard
solution with a known concentration of theophylline in the
same medium as reference.
Model dependent parameters
Three mathematics models were applied to interpret
dissolution kinetic, in order to determine the process order:
first-order model, zero-order model and Higuchi model
(Abdou, Hanna, Muhammad, 2000; Ferraz, Consiglieri,
Storpirtis, 1998; Shah, Noory, Noory, 1995)
Dissolution Efficiency
Dissolution efficiency (DE) was graphically
calculated from dissolved drug percentage versus time
curves (Khan, Rhodes, 1975). Variance analysis (ANOVA)
was used to check the existence of significant differences
between DE data.
Model independent parameters
Data from dissolution profiles of chosen batches and
the brand medication (Laboratory B) were submitted to
simple independent model employing a difference factor
(f1) and a similarity factor (f2) to compare the dissolution
profiles (Costa, 2001; Shah et al., 1998).
TABLE I  - Composition of compounded extended-release capsules with 100 mg of theophylline and
hydroxypropylmethylcellulose (HPMC, MethocelTM K100MPRCR, K15MPRCR e E4MCR), using volumetric method
for powder filling capsules in batches of 50.
Powder material MEK100M1 MEK100M2 MEK100M3 MEK15M1 MEE4M1 MEE4M351
(mg) (%)  (mg)  (%)  (mg)  (%)  (mg)  (%)  (mg)  (%)  (mg)  (%)
Theophylline 100.0 57.14 100.0 48.78 100.0 41.32 100.0 37.45 100.0 37.45 100.0 37.45
MethocelTM K100M 75.0 42.86 50.0 24.39 37.4 15.46 0.00 0.00 0.00 0.00 0.00 0.00
MethocelTM K15M 0.00 0.00 0.00 0.00 0.00 0.00 75.0 28.09 0.0 0.00 0.00 0.00
MethocelTM E4M 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 75.0 28.09 87.4 32.73
Lactose 0.00 0.00 55.0 26.83 104.6 43.22 92.0 34.46 92.0 34.46 79.6 29.82
Total 175.0 100.0 205.0 100.0 242.0 100.0 267.0 100.0 267.0 100.0 267.0 100.0
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RESULTS AND DISCUSSION
Official specifications establish that, for hard
capsules up to 300.0 mg, the weight variation allowed is ±
10.0%, and it is not allowed more than two units out of the
specification and none of them can be above or under the
double of the indicated percentage. The results of weight
variation presented in the Tables II and III showed that all
the capsules complied with the Pharmacopeia
specifications (United States Pharmacopeia, 2005).
The compounded capsules showed theophylline
amount between 94.6% and 101.22%, and those from the
commercial batches B1 and B2 showed 104.45%,
respectively, therefore in accordance with the official
specifications (United States Pharmacopeia, 2005) (Tables
II and III).
The three types of tested MethocelTM showed
decrease of theophylline release from the capsules (Figures
1 and 2).
According to the dissolution profiles results, the
increase of HPMC content, as well as the use of higher
viscosity polymers in the formulations, resulted in the
decrease of theophylline dissolution rate in compounded
capsules. The capsules from the formulation MEE4M351,
with 35% (wt/wt) of MethocelTM E4MCR, presented
dissolved amount of theophylline in accordance with the
specifications of American Pharmacopeia 28th ed, Test 8.
From this formulation, ten batches were compounded
to check the reproducibility of the process (Figure 2). All
the batches showed dissolved quantities of theophylline in
accordance with the specified limits (United States
Pharmacopeia, 2005).
When the dissolution profiles of the ten batches of the
formulation MEE4M351 and the brand medication
(Laboratory B1) were compared through the independent
model employing difference factor (f1) and similarity factor
(f2), it was possible to verify that f1 values above 15 and
f2 values under 50 were obtained. This means that the
compounded formulations showed different dissolution
profiles when compared to the studied commercial products
(Table IV).
To analyze the variance among the average values of
Dissolution Efficiency (DE) obtained from chosen
developed batches (Figure 3),the Variance Analysis
“ANOVA: Unique Factor” was used . This tool performed
a simple variance analysis, in order to check if there was
significant difference among the values of DE.
TABLE III - Results of weight variation and assay of
commercial capsules with 100 mg of prolonged-release
theophylline microgranules
Product Weight Assay
(Laboratories) variation (mg) (%)
(CV%)
B1 (brand medication) 161.76 (1.17)* 102.38
B2 (brand medication) 154.56 (1.80)* 104.45
CV = Coefficient of Variation; CV = n = 10 determinations;
CV* = n = 5 determinations.
TABLE II - Results of weight variation and assay of
compounded extended-release capsules with 100 mg of
theophylline
Products Weight Assay
(Batches) variation (mg) (%)
(CV%)*
MEK100M1 176.93 (3.87)  97.84
MEK100M2 205.02 (2.57)  99.02
MEK100M3 242.51 (2.50) 100.41
MEK15M1 254.69 (2.91)  94.60
MEE4M1 257.44 (2.13)  99.61
MEE4M351 271.91 (1.87) 100.30
MEE4M352 270.47 (1.97) 100.76
MEE4M353 274.70 (1.51)  99.40
MEE4M354 275.16 (1.56) 100.85
MEE4M355 270.14 (2.88) 101.22
MEE4M356 274.59 (1.76)  99.12
MEE4M357 274.14 (2.36)  99.08
MEE4M358 273.71 (1.22) 100.98
MEE4M359 272.75 (1.83) 100.42
MEE4M3510 274.51 (1.91) 100.67
*Coefficient of Variation; CV = n = 20 determinations.
TABLE IV - Results of difference factor (f1) and similarity
factor (f2) to compare the dissolution profiles
Compounded Difference Similarity
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FIGURE 1 – Release profiles of theophylline capsules with MethocelTM K100MPRCR, K15MPRCR and E4MCR.
FIGURE 2 – Release profiles of theophylline capsules with MethocelTM E4MCR and Brand medication.
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In this case, it was assumed as null hypothesis that
the average of two ou more samples are equals (from
population with the same average).
According to Table V, the found value of F was 2.07,
and the value of F necessary to 5% significance is 2.12.
Therefore, there is no significant difference among the
compounded batches.
The kinetic models most adequated to the
preparations and the obtained values for the correlation
coefficient (r) of the compounded formulations are
described in Table VI.
According to the correlation coefficients observed,
excepted the formulation MEE4M3510, the reproduced
batches followed first-order kinetic process, indicating that
the dissolution rate of solid particles in a liquid medium
depends of the relation between the dissolved amount of
FIGURE 3 – Medium values of DE (%) for compounded batches.
TABLE V – Analysis of variance (ANOVA) of Dissolution Efficiency (DE) results of each studied batch
Source Of Variation Degrees of Freedom Sum of Squares Mean Square F
Between groups 9 268.025 29.781 2.07*
Within groups 40 576.189 14.405
Total 49 844.214
*p = 0.0563
drug and the remaining amount of it in the matrix. This
means that, possibly, the process occurs as a result of the
drug diffusion through the jelly layer and the erosion of the
matrix system, process known as Non-Fickian or
anomalous.
Only the formulation MEE4M3510, with a
correlation coefficient of 0.9925, followed the Higuchi
model, in which the quantity of drug released is directly
proportional to the “t. In fact, it was not expected that the
release followed the Higuchi model, since this model
considers the drug release as a diffusion process based on
the first law of Fick, not considering other mechanisms, like
drug release by erosion.
In the systems that employ hydrophilic matrices to
control slightly soluble drug release, the predominant
mechanism is generally erosion (Sako et al., 2002). In the
Development and “in vitro” evaluation of extended-release theophylline matrix capsules 259
case of compounded slow-release capsules, besides this
consideration, it must be remembered that due to low
compaction, the jelly layer formed by MethocelTM when in
contact with the medium tends to be less rigid than one
provided from a formulation with the same polymer in
tablets dosage forms, due to a higher porosity of the capsule
(Bogner, Szwejkowski, Houston, 2001), meeting the first-
order model found.
In the dissolution profiles of the commercial capsules
with prolonged release of 100 mg theophylline
microgranules, it was showed that the formulations
presented quick release of the drug, with dissolved amount
of theophylline percentage of 104.28% in 60 minutes and
97.18% in 60 minutes (Figure 4), indicating that in these
formulations the drug release is not a limit factor to the
absorption. They did not complied with the specifications
of the Test 8 (United States Pharmacopeia, 2005).
TABLE VI – Correlation coefficients (r) obtained from mathematical treatment of dissolution kinetics data.
Formulations Zero-order First-order Higuchi Models
MEE4M351 0.9584 0.9975 0.9939 First-order
MEE4M352 0.9254 0.9951 0.9906 First-order
MEE4M353 0.9173 0.9941 0.9888 First-order
MEE4M354 0.9600 0.9987 0.9901 First-order
MEE4M355 0.9659 0.9936 0.9879 First-order
MEE4M356 0.9422 0.9993 0.9935 First-order
MEE4M357 0.9388 0.9973 0.9912 First-order
MEE4M358 0.9411 0.9975 0.9905 First-order
MEE4M359 0.9511 0.9987 0.9899 First-order
MEE4M3510 0.9555 0.9914 0.9925 Higuchi
FIGURE 4 – Release profiles of commercial capsules with prolonged release of 100 mg theophylline microgranules.
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CONCLUSION
It was possible to obtain compounded modified
release matrix capsules with theophylline using different
types of hydroxypropylmethylcellulose, like MethocelTM
K100MPRCR, MethocelTM K15MPRCR and MethocelTM
E4MCR, to decrease the drug release rate. The formulation
with 35% (wt/wt) of MethocelTM E4MCR was the one
which met the specifications of dissolved drug percentage.
Also, it is possible to obtain reproducibility of dissolved
drug percentage in extended-release compounded capsules.
RESUMO
Desenvolvimento e avaliação in vitro de cápsulas de
teofilina de liberação prolongada
Cápsulas de liberação modificada contendo 100 mg de
teofilina foram preparadas com polímeros derivados da
celulose (Methocel® K100MPRCR, K15MPRCR e
E4MCR) em diferentes concentrações, 15-35%, empre-
gando-se o método volumétrico. Estudos de liberação do
fármaco foram realizados de acordo com a Farmacopéia
Americana 28 ed., (Teste 8), empregando aparato 1, rota-
ção de 100 rpm e temperatura de 37 oC em 900 mL de
meio fluido intestinal sem enzimas (pH 7,5). Os perfis de
dissolução foram comparados ao de duas especialidades
farmacêuticas comerciais. A formulação, com 35% de
Methocel® E4MCR, evidenciou perfis de liberação de
acordo com as especificações e os resultados foram
reprodutíveis para 10 lotes manipulados com a mesma
formulação. As cápsulas comerciais de liberação prolon-
gada contendo 100 mg de teofilina (microgrânulos), sub-
metidas ao mesmo ensaio, apresentaram rápida liberação
do fármaco, indicando que a liberação não é fator
limitante para a absorção. Avaliou-se a cinética de libe-
ração do fármaco empregando os modelos matemáticos
de ordem zero, primeira ordem e Higuchi. Conclui-se que
as matrizes obtidas foram capazes de modular a libera-
ção, envolvendo os mecanismos de difusão e erosão, pre-
valecendo o modelo de primeira ordem e que as cápsulas
de liberação modificada podem ser manipuladas, desde
que testes de liberação sejam realizados.
UNITERMOS: Teofilina. Cápsulas. Liberação prolonga-
da. Dissolução.
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